



FOR IMMEDIATE RELEASE:

Notice of Substantial Holder

Date of release amended

BELLEVILLE, ON, May 17, 2013 – On April 25, 2013 Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC) became aware that Mr. William Wells became a beneficial shareholder of BNC, which has caused him to become a substantial holder in BNC (within the meaning of section 671B) of the *Australian Corporations Act 2001* (Cth). On May 14, 2013 BNC was advised that Mr. Wells became a registered holder of these same shares. As far as BNC is aware Mr. Wells holds 5,853,322 BNC shares, representing approximately 5.57% of the issued capital in BNC as of today's date.

BNC is not aware as to whether Mr. Wells has a relevant interest in any additional BNC shares by virtue of any further indirect holdings or through any associates.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.

For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

For further information, please contact:

Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.

Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058

Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097

Jennifer.Shea@Bioniche.com